From the Department of Biology and the McCollum-Pratt Institute, The Johns Hopkins University, Baltimore, Maryland 21218
Received for publication, May 15, 2000, and in revised form, October 25, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Orf135 from Escherichia coli is a new
member of the Nudix (nucleoside diphosphate
linked to some other moiety, x) hydrolase family of enzymes
with substrate specificity for CTP, dCTP, and 5-methyl-dCTP. The gene
has been cloned for overexpression, and the protein has been
overproduced, purified, and characterized. Orf135 is most active on
5-methyl-dCTP (kcat/Km = 301,000 M The Nudix hydrolases are a family of enzymes catalyzing the
hydrolysis of substrates consisting of a nucleoside
diphosphate linked to some other moiety, x
(hence, the acronym Nudix), and are defined by the signature sequence
GX5EX7REUXEEXGU
where U is a bulky aliphatic amino acid, Ile, Leu, or Val (1). The family consists of enzymes that hydrolyze (d)NTPs (2-8), NADH (9, 10),
GDP-mannose (11), ADP-ribose (10, 12-14), diadenosine polyphosphates
(10, 15-21), and diphosphoinositol polyphosphates in addition to
diadenosine polyphosphates (22-24). The Nudix hydrolases were
discovered first through a comparison of Escherichia coli MutT and Streptococcus pneumoniae MutX and from BLAST
(25) searches of MutT, which revealed the signature sequence, common in
a number of open reading frames (26, 27). The family has grown to
include over 450 open reading frames in over 85 species as well as a
variety of enzymes as indicated above. Nudix hydrolases are ubiquitous throughout nature, existing in eukaryotes, prokaryotes, and archaea (12) and appear to control the level of potentially toxic substances that would be detrimental to the cell at elevated levels (1, 23) and to
regulate the accumulation of metabolic intermediates (1, 23).
Orf135 is a true member of the Nudix hydrolase family; it contains the
signature sequence
GX5EX7REUXEEXGU
and it cleaves the nucleoside diphosphate derivatives CTP, dCTP, and
5-methyl-dCTP. Yet, it is unique in its substrate specificity, because
it is the first Nudix hydrolase highly specific toward pyrimidine
substrates. In this paper, we describe the cloning and expression of
the orf135 gene and the purification and characterization of
the Orf135 enzyme, and we discuss its possible role in intermediary metabolism.
Materials
Nucleic Acids--
Oligodeoxynucleotides were obtained from
Integrated DNA Technologies, the plasmid pET11b was from Novagen, and
chromosomal DNA from E. coli strain MG1655 was kindly
provided by Dr. Frederick R. Blattner (University of Wisconsin).
Bacterial Strains--
Competent cells of E. coli
DH5 Enzymes--
Pfu DNA polymerase was from Strategene,
restriction enzymes NdeI and BamHI and T4 DNA
ligase were obtained from Life Technologies, Inc., and inorganic
pyrophosphatase came from Sigma.
Chemicals--
Isopropyl- Methods
Cloning--
The orf135 gene was amplified from
E. coli strain MG1655 chromosomal DNA using polymerase chain
reaction. An NdeI restriction site was incorporated at the
start of the gene and a BamHI site at its end using
oligodeoxynucleotide primers containing these sites. The amplified gene
was purified, digested with NdeI and BamHI, and
ligated into the respective restriction sites of plasmid pET11b to
place the orf135 gene under control of a T7
lac promoter for expression. The resultant plasmid,
pETorf135, was used to transform E. coli strain DH5 Expression and Enzyme Purification--
E. coli
strain HMS174(DE3) containing pETorf135 was grown at 37 °C in 2 liters of broth containing 100 µg/ml ampicillin. When growth reached
an A600 of 0.8, the culture was induced with 1 mM isopropyl-
Orf135 was extracted from the frozen cells by resuspending them in 2 volumes of buffer A (50 mM Tris, pH 7.5, 1 mM
EDTA, 0.1 mM dithiothreitol). Prior freezing was necessary
to render the protein extractable in this manner. The suspension was
centrifuged, and the supernatant (Fraction I) containing ~80 mg of
protein was concentrated by precipitation with 65% ammonium sulfate
and dissolved in 1.2 ml of buffer A (Fraction II). Fraction II
(containing ~65 mg of protein) was loaded onto a 1.5 × 52-cm
Sephadex G50 gel filtration column (calibrated with molecular
mass standards of 14, 20, and 29 kDa) and eluted with buffer A
containing 200 mM NaCl. The fractions containing Orf135 and
essentially free of other proteins were combined (Fraction III) and
concentrated by precipitation with 80% ammonium sulfate, dissolved in
buffer A to a final volume of 2 ml (Fraction IV), and stored at
Enzyme Assays--
A standard reaction mixture of 50 µl
contained 50 mM Tris-HCl, pH 9, 1 mM
dithiothreitol, 5 mM MgCl2, 4 mM
substrate (CTP), 500 milliunits of inorganic pyrophosphatase, and
0.3-5 milliunits of Orf135. The mixture was incubated at 37 °C for
15 min, stopped by the addition of 50 µl of 4 parts Norit (20%
packed volume) and 1 part 7% perchloric acid, and centrifuged, and 50 µl of the supernatant was analyzed for inorganic orthophosphate by
the colorimetric procedure of Ames and Dubin (28). One unit of Orf135
hydrolyzes 1 µmol of substrate/min.
To identify the products and stoichiometry of the reaction, the
standard reaction mixture was scaled up 20-fold, inorganic pyrophosphatase was omitted, and the reactions were quenched with excess EDTA (relative to magnesium). The substrate and nucleotide product were quantitated using a high performance liquid chromatography system with a YMC ODS-AM column, and an isocratic mobile phase of 12.5 mM citric acid, 25 mM sodium acetate,
10 mM acetic acid, adjusted to pH 6.3 with sodium
hydroxide. The substrate and nucleotide product were detected at 254 nm
and identified with standards of CTP, CDP, and CMP. Inorganic
pyrophosphate was quantitated by the colorimetric assay after
hydrolysis to inorganic orthophosphate by boiling for 15 min in
0.5 M HCl.
Kinetic studies were carried out using a 0.1-4 mM
substrate, 5 mM MgCl2, and 0.1-5 milliunits of Orf135.
Assay for Mutator Phenotype--
orf135 was subcloned from
pETorf135 and into a pTRC99A vector containing an E. coli
lac promoter, transformed into E. coli strain SB3 lacking a functional mutT gene, and mutation
frequencies were determined as described in O'Handley et
al. (8).
Subcloning, Expression, and Purification
We identified the orf135 gene, which had been sequenced
and deposited as part of the E. coli sequencing project
(29), from a BLAST search (30) of the Nudix signature sequence in MutT. The gene was cloned directly from chromosomal DNA as described under
"Methods," and its sequence agrees with that reported in the
GenbankTM. Expression of orf135 results in the
appearance of a major band on a denaturing polyacrylamide gel
corresponding to a 15-kDa protein, not readily detectable by eye in the
same strain of E. coli containing pET11b without the insert
(Fig. 1). As has been reported for other Nudix hydrolase enzymes (8, 11, 14, 18), a majority of the Orf135 is
released into solution simply by freezing and thawing the cells,
leaving most of the other proteins behind in the cell. This results in
an extract much more highly enriched in Orf135 than would ensue from a
more complete disruption of the cells, such as that caused by
sonication, and it greatly simplifies purification, requiring only an
additional ammonium sulfate fractionation and gel filtration
step. This procedure yields ~25 mg of essentially pure enzyme
from a 2-liter preparation (Fig. 1).
1
s
1), followed by CTP
(kcat/Km = 47,000 M
1 s
1)
and dCTP (kcat/Km = 18,000 M
1 s
1).
Unlike other nucleoside triphosphate pyrophophohydrolases of the Nudix
hydrolase family discovered thus far, Orf135 is highly specific for
pyrimidine (deoxy)nucleoside triphosphates. Like other Nudix
hydrolases, the enzyme cleaves its substrates to produce a nucleoside
monophosphate and inorganic pyrophosphate, has an alkaline pH optimum,
and requires a divalent metal cation for catalysis, with magnesium
yielding optimal activity. Because of the nature of its substrate
specificity, Orf135 may play a role in pyrimidine biosynthesis, lipid
biosynthesis, and in controlling levels of 5-methyl-dCTP in the cell.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
were obtained from Life Technologies, Inc., and E. coli HMS174(DE3) was from Novagen.
-D-thiogalactopyranoside
was from Research Organics and Sephadex G50 from Pharmacia Biotech,
nucleotide substrates were from Sigma, and other general chemicals were
from Sigma or J. T. Baker, Inc.
for
storage and E. coli strain HMS174(DE3) for expression. The
sequence of orf135 in the resultant plasmid was confirmed
using the fluorescent dideoxy terminator method on a PerkinElmer ABI
377 automated DNA sequencer by the DNA analysis facility at The
Johns Hopkins University.
-D-thiogalactopyranoside and
grown for an additional 2 h, and the cells (3.5 g) were harvested,
washed in buffered isotonic saline solution, recentrifuged, and stored
at
80 °C.
80 °C where Orf135 was stable indefinitely. Fraction IV contained
25 mg of protein with 2300 units of CTPase activity.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (72K):
[in a new window]
Fig. 1.
Expression and purification of the Orf135
protein. A 15% polyacrylamide gel containing 1% SDS contained
the following: lane 1, reference proteins with molecular
masses of 66, 45, 36, 29, 24, 20, 14, and 6.5 kDa; lane 2,
crude extract from cells containing pET11b; lane 3, crude
extract from cells containing pETorf135; lane 4, Fraction I,
supernatant obtained from freezing and thawing the cells; lane
5, Fraction IV, obtained from purification over a G50 column and
concentration of pooled fractions. Lanes 3-5 each contain 3 µg of protein. Lane 2 contains an amount of crude extract
comparable to that in lane 3.
Orf135 migrates on a denaturing polyacrylamide gel as expected for the 15-kDa polypeptide predicted from its amino acid composition, and it elutes from a G50 gel filtration column as expected for a monomer of this size.
Substrate Specificity
Like MutT and Orf17, Orf135 is a (deoxy)ribonucleoside triphosphatase. However, the substrate specificity is markedly different for these three enzymes. Whereas MutT and Orf17 hydrolyze all 8 canonical nucleoside triphosphates with preference for dGTP and dATP, respectively (2, 8), Orf135 is very specific for CTP, dCTP, and 5-methyl-dCTP (Table I). This is the first (deoxy)ribonucleoside triphosphatase of the Nudix hydrolase family that is base-specific and the first Nudix hydrolase in general that is specific for pyrimidine substrates (1). Orf135 hydrolyzes UTP and dTTP at less than 5% of the rate of CTP, and there is no significant hydrolysis of ATP, dATP, GTP, or dGTP. Also, as we have observed with MutT and Orf17, cleavage of the pyrophosphate linkage in the nucleoside diphosphates by Orf135 is minimal, and cleavage of the nucleoside monophosphates by Orf135 is undetectable.
|
The influence of the various functional groups of the substrates on the
rate of hydrolysis is compared in Fig. 2.
5-Methyl-dCTP and CTP have an amino group at the C4 position, which is
replaced in dTTP and UTP by a keto group. 5-Methyl-dCTP and CTP are
hydrolyzed at rates 50 times greater than dTTP and UTP, respectively,
indicating the importance of the C4 amino group for recognition and
catalysis. Likewise, 5-methyl-dCTP is hydrolyzed more rapidly than dCTP
and dTTP at a higher rate than dUTP, both by a factor of ~5,
indicating that the 5-methyl group also enhances the overall rate,
although not as dramatically as the influence of the C4 amino group. As for the sugar, the presence of the hydroxyl group at the C2' position does not have that great of an effect on activity (the rate of hydrolysis of CTP is double that of dCTP), but epimerization of the
hydroxyl group at the C2' position decreases activity by ~20-fold as
indicated by a comparison of cleavage of CTP versus ara-CTP. It will be interesting to examine whether these important functional groups on the substrates make vital contacts with amino acids in the
protein by analyzing a three-dimensional structure of the enzyme
complexed with the substrate.
|
A kinetic analysis of the preferred substrates (Table II) shows that Orf135 cleaves 5-methyl-dCTP with a catalytic efficiency 6 times greater than that for CTP and 17 times greater than that for dCTP. The possible biological significance of these differences will be discussed below.
|
Requirements of the Enzyme
pH Optimum-- Orf135 has optimal activity between pH 8.5 and 9.0 in Tris-HCl or glycine buffers with the rate dropping to 50% at pH 7.8 and 9.8. This alkaline pH optimum is typical of the Nudix hydrolase family of enzymes (with the pH optima for MutT, Orf17, Orf257, Orf186, and Orf1.9 being pH 9.0, 8.6, 8.5, 9.3, and 9.0, respectively (2, 8-11)), indicating a common mechanism of hydrolysis as discussed previously by O'Handley et al. (10).
Divalent Cation Requirement-- As with all of the other Nudix hydrolases discovered thus far, Orf135 absolutely requires a divalent metal cation for activity. Magnesium is most effective with optimal activity at 5 mM Mg2+ in the presence of 4 mM substrate. Mn2+ can partially substitute for Mg2+ with ~10% activity at optimal concentration, whereas no activity was observed in the presence of Zn2+, Co2+, or Ca2+.
Product Formation
The products of the hydrolysis of CTP were determined from a
scaled-up, standard reaction excluding inorganic pyrophosphatase. The
decrease of CTP and increase of the nucleotide product, CMP, during the course of the reaction were monitored over time by chromatographic analysis as shown in Fig.
3. The other product formed, inorganic
pyrophosphate, was quantified by the colorimetric assay of Ames and
Dubin (28) after hydrolysis to inorganic orthophosphate, as described
under "Methods"; this is also shown in Fig. 3. The CTP hydrolyzed
corresponds to the CMP and inorganic pyrophosphate produced in a 1:1
molar ratio at each time point. No CDP was detected throughout the
reaction, and no inorganic orthophosphate appeared, as analyzed by the
method of Fiske and Subbarow (31), which is specific for
inorganic orthophosphate and will not detect pyrophosphate. Thus, the
hydrolysis of CTP catalyzed by Orf135 may be written as follows
(Reaction 1).
![]() |
![]() |
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
As can be seen from a list of the known Nudix hydrolase enzymes,
Orf135 fits in well as a member of the Nudix hydrolase family (Fig.
4). All of the other enzymes are distinct
from Orf135, but they all share the common signature sequence
(GX5EX7REUXEEXGU where U is Ile, Leu, or Val) characteristic of this family (1), and
they all hydrolyze nucleoside diphosphate compounds.
|
A BLAST search using Orf135 as the query identifying many of these
previously discovered Nudix hydrolases, as well as a number of unknown
open reading frames, is shown in Fig. 5.
The closest matches to identified enzymes are to MutT from
Proteus vulgaris, Haemophilus influenzae,
and E. coli with E values of 5 × 1010, 3 × 10
9, and 8 × 10
8, respectively. Also, when threading
programs were used to compare the predicted structures of Orf135 and
the other Nudix hydrolases to the solved NMR solution structure of
MutT, Orf135 had the highest match of any of the known, characterized
Nudix hydrolases (results not shown). However, as described throughout
this paper, Orf135 is distinct from MutT in its substrate specificity,
preferentially hydrolyzing CTP, dCTP, and 5-methyl-dCTP as opposed to
dGTP. Because Orf135 appears more similar to MutT in primary and
predicted secondary structure than other Nudix hydrolases, it was
important to ascertain whether the cellular roles of Orf135 and MutT
are distinctly different from one another. Accordingly, a plasmid
carrying the orf135 gene was transformed into a
mutT
strain of E. coli and analyzed for a
decrease in mutation frequency. Orf135 did not complement MutT (results
not shown). This result was not surprising to us, because no other
Nudix hydrolases except MutT orthologs active on dGTP have been shown
to complement MutT (8, 12),1
and it demonstrates that even open reading frames with similar primary
and (predicted) secondary structures can have different enzymatic
activities and cellular functions. Thus, as we have pointed out (1),
caution must be exercised when analyzing information from BLAST
searches and data bases of proteins containing the Nudix signature
sequence. For example, the Japanese E. coli sequencing project lists Orf135 (accession number BAA15549) as a mutator MutT protein or dGTP pyrophosphohydrolase, whereas the report for
Orf135 (accession number AAC74829), deposited by Blattner's group (29)
as part of their sequencing of E. coli, simply states that
Orf135 is 37% identical to 125 residues of MutT from H. influenzae.
|
What then is the possible function of Orf135 in the cell? The best substrates discovered for Orf135 in vitro are CTP, dCTP, and 5-methyl-dCTP. The role of Orf135 may be to regulate the levels of these compounds or other cytidine triphosphate analogs in the cell as discussed below.
Methylation of the C5 position of cytosine by DNA (cytosine-5-) methyltransferase is involved in the differential control of gene expression (33). As a result of DNA degradation, 5-methyl-dCMP is produced. In human cells, nucleoside monophosphate kinase does not appear to recognize 5-methyl-dCMP as a substrate, and thus phosphorylation of 5-methyl-dCMP to 5-methyl-dCTP does not occur (34, 35). It has been suggested that this prevents 5-methylcytosine from being randomly incorporated into DNA, since 5-methyl-dCTP is an excellent analogue of dCTP and can replace it completely (36). No similar studies have been reported for E. coli, and so the significance of 5-methyl-dCTPase here is moot. There are, however, bacteriophages that induce kinases that can phosphorylate 5-methyl-dCMP (37) and 5-hydroxymethyl-dCMP (38), and Orf135 could be part of a defense mechanism against infection.
Furthermore, Orf135 may monitor the intracellular accumulation of CTP, a key metabolite in both pyrimidine and lipid biosynthesis. Orf135 may play a role in regulating the synthesis of pyrimidines in E. coli by hydrolyzing CTP. CTP is the negative regulator of the entire pyrimidine biosynthetic pathway in E. coli, binding to aspartate transcarbamoylase, the committed step in the synthesis of UTP and CTP (39). If CTP accumulates, its inhibition of aspartate transcarbamoylase not only inhibits its own synthesis but also the synthesis of UMP, UDP, and UTP. Because dTMP is synthesized from other pyrimidine deoxyribonucleotides with the common pyrimidine precursor being UMP, the synthesis of dTMP would also be inhibited by CTP accumulation. This would ultimately affect DNA synthesis. Orf135 may circumvent these effects through hydrolysis of CTP. It is interesting to note that dATP, the major negative regulator of the deoxynucleotide biosynthetic pathway, is the substrate of another Nudix hydrolase, Orf17 from E. coli, which hydrolyzes it to dAMP and pyrophosphate (8).
In lipid biosynthesis, CTP is utilized in the synthesis of
CDP-ethanolamine and CDP-diacylglycerol, both important intermediates in the synthesis of glycerophospholipids, which are major components of
cell membranes (40). There have been several studies showing a direct
correlation between CTP levels and phospholipid biosynthesis. Overexpression of CTP synthetase (41) or expression of a CTP synthetase
mutant less sensitive to inhibition by CTP (42) causes an increase in
CTP levels, leading to an increase in phospholipids and neutral lipids.
On the other hand, when cyclopentenylcytosine, a potent and specific
inhibitor of CTP synthetase, was added to cells, the pool size of CTP
dropped to ~10% of controls, and phospholipid biosynthesis was
rerouted away from CTP-utilizing reactions toward neutral lipid
biosynthesis (43). As pointed out by Hatch and McClarty (43), "the
cellular CTP level may be a universal signal or switch for all
phospholipid biosynthesis." Thus, the regulation of CTP levels is
vital to the cell, and Orf135 may play a role in this regard.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grant GM 18649. This is publication 1523 from the McCollum-Pratt Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Dept. of Chemistry, University of Richmond,
Richmond, VA 23173. To whom correspondence should be addressed. Tel.:
804-289-8245; Fax: 804-287-1897; E-mail: sohandle@richmond.edu.
Published, JBC Papers in Press, October 26, 2000, DOI 10.1074/jbc.M004100200
1 S. F. O'Handley, C. A. Dunn, and M. J. Bessman, personal observations.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Bessman, M. J.,
Frick, D. N.,
and O'Handley, S. F.
(1996)
J. Biol. Chem.
271,
25059-25062 |
2. |
Bhatnagar, S. K.,
Bullions, L. C.,
and Bessman, M. J.
(1991)
J. Biol. Chem.
266,
9050-9054 |
3. | Mo, J. Y., Maki, H., and Sekiguchi, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11021-11025[Abstract] |
4. |
Kakuma, T.,
Nishida, J.,
Tsuzuki, T.,
and Sekiguchi, M.
(1995)
J. Biol. Chem.
270,
25942-25948 |
5. | Cai, J. P., Kakuma, T., Tsuzuki, T., and Sekiguchi, M. (1995) Carcinogenesis 16, 2343-2350[Abstract] |
6. | Kamath, A. V., and Yanofsky, C. (1993) Gene 134, 99-102[CrossRef][Medline] [Order article via Infotrieve] |
7. |
Bullions, L. C.,
Mejean, V.,
Claverys, J. P.,
and Bessman, M. J.
(1994)
J. Biol. Chem.
269,
12339-12344 |
8. |
O'Handley, S. F.,
Frick, D. N.,
Bullions, L. C.,
and Bessman, M. J.
(1996)
J. Biol. Chem.
271,
24649-24654 |
9. |
Frick, D. N.,
and Bessman, M. J.
(1995)
J. Biol. Chem.
270,
1529-1534 |
10. |
O'Handley, S. F.,
Frick, D. N.,
Dunn, C. A.,
and Bessman, M. J.
(1998)
J. Biol. Chem.
273,
3192-3197 |
11. |
Frick, D. N.,
Townsend, B. D.,
and Bessman, M. J.
(1995)
J. Biol. Chem.
270,
24086-24091 |
12. |
Sheikh, S.,
O'Handley, S. F.,
Dunn, C. A.,
and Bessman, M. J.
(1998)
J. Biol. Chem.
273,
20924-20928 |
13. | Raffaelli, N., Lorenzi, T., Amici, A., Emanuelli, M., Ruggieri, S., and Magni, G. (1999) FEBS Lett. 444, 222-226[CrossRef][Medline] [Order article via Infotrieve] |
14. |
Dunn, C. A.,
O'Handley, S. F.,
Frick, D. N.,
and Bessman, M. J.
(1999)
J. Biol. Chem.
274,
32318-32324 |
15. | Thorne, N. M., Hankin, S., Wilkinson, M. C., Nunez, C., Barraclough, R., and McLennan, A. G. (1995) Biochem. J. 311, 717-721[Medline] [Order article via Infotrieve] |
16. | Hankin, S., Wintero, A. K., and McLennan, A. G. (1997) Int. J. Biochem. Cell Biol. 29, 317-323[CrossRef][Medline] [Order article via Infotrieve] |
17. | Maksel, D., Guranowski, A., Ilgoutz, S. C., Moir, A., Blackburn, M. G., and Gayler, K. R. (1998) Biochem. J. 329, 313-319[Medline] [Order article via Infotrieve] |
18. |
Conyers, G. B.,
and Bessman, M. J.
(1999)
J. Biol. Chem.
274,
1203-1206 |
19. |
Cartwright, J. L.,
and McLennan, A. G.
(1999)
J. Biol. Chem.
274,
8604-8610 |
20. | Ingram, S. W., Stratemann, S. A., and Barnes, L. D. (1999) Biochemistry 38, 3649-3655[CrossRef][Medline] [Order article via Infotrieve] |
21. | Cartwright, J. L., Britton, P., Minnick, M. F., and McLennan, A. G. (1999) Biochem. Biophys. Res. Commun. 256, 474-479[CrossRef][Medline] [Order article via Infotrieve] |
22. |
Safrany, S. T.,
Caffrey, J. J.,
Yang, X.,
Bembenek, M. E.,
Moyer, M. B.,
Burkhart, W. A.,
and Shears, S. B.
(1998)
EMBO J.
17,
6599-6607 |
23. | McLennan, A. G. (1999) Int. J. Mol. Med. 4, 79-89[Medline] [Order article via Infotrieve] |
24. |
Safrany, S. T.,
Ingram, S. W.,
Cartwright, J. L.,
Falck, J. R.,
McLennan, A. G.,
Barnes, L. D.,
and Shears, S. B.
(1999)
J. Biol. Chem.
274,
21735-21740 |
25. | Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410[CrossRef][Medline] [Order article via Infotrieve] |
26. | Mejean, V., Salles, C., Bullions, L. C., Bessman, M. J., and Claverys, J. P. (1994) Mol. Microbiol. 11, 323-330[Medline] [Order article via Infotrieve] |
27. | Koonin, E. V. (1993) Nucleic Acids Res. 21, 4847[Medline] [Order article via Infotrieve] |
28. | Ames, B. N., and Dubin, D. T. (1960) J. Biol. Chem. 235, 769-775[Medline] [Order article via Infotrieve] |
29. |
Blattner, F. R.,
Plunkett, G., III,
Bloch, C. A.,
Perna, N. T.,
Burland, V.,
Riley, M.,
Collado-Vides, J.,
Glasner, J. D.,
Rhode, C. K.,
Mayhew, G. F.,
Gregor, J.,
Davis, N. W.,
Kirkpatrick, H. A.,
Goeden, M. A.,
Rose, D. J.,
Mau, B.,
and Shao, Y.
(1997)
Science
277,
1453-1462 |
30. |
Altschul, S. F.,
Madden, T. L.,
Schaffer, A. A.,
Zhang, J.,
Zhang, Z.,
Miller, W.,
and Lipman, D. J.
(1997)
Nucleic Acids Res.
25,
3389-3402 |
31. |
Fiske, C. H.,
and Subbarow, Y.
(1925)
J. Biol. Chem.
66,
375-400 |
32. |
Weber, D. J.,
Bhatnagar, S. K.,
Bullions, L. C.,
Bessman, M. J.,
and Mildvan, A. S.
(1992)
J. Biol. Chem.
267,
16939-16942 |
33. | Siegfried, Z., and Cedar, H. (1997) Curr. Biol. 7, 305-307 |
34. | Vilpo, J. A., and Vilpo, L. M. (1991) Mutat. Res. 256, 29-35[Medline] [Order article via Infotrieve] |
35. | Vilpo, J. A., and Vilpo, L. M. (1993) Mutat. Res. 286, 217-220[Medline] [Order article via Infotrieve] |
36. | Bessman, M. J., Lehman, I. R., Adler, J., Zimmerman, S. G., Simms, E. S., and Kornberg, A. (1958) Proc. Natl. Acad. Sci. U. S. A. 44, 633 |
37. | Wang, R. Y., Huang, L. H., and Ehrlich, M. (1982) Biochim. Biophys. Acta 696, 31-36[Medline] [Order article via Infotrieve] |
38. |
Mathews, C. K.,
Brown, F.,
and Cohen, S. S.
(1964)
J. Biol. Chem.
239,
2957 |
39. | Neuhard, J., and Kelln, R. A. (1996) in Escherichia coli and Salmonella (Neidhardt, F. C., ed), 2nd. Ed., Vol. 1 , pp. 580-599, ASM Press, Washington, D. C. |
40. | Cronan, J. E. J., and Rock, C. O. (1996) in Escherichia coli and Salmonella (Neidhardt, F. C., ed), 2nd Ed., Vol. 1 , pp. 612-636, ASM Press, Washington, D. C. |
41. |
McDonough, V. M.,
Buxeda, R. J.,
Bruno, M. E.,
Ozier-Kalogeropoulos, O.,
Adeline, M. T.,
McMaster, C. R.,
Bell, R. M.,
and Carman, G. M.
(1995)
J. Biol. Chem.
270,
18774-18780 |
42. |
Ostrander, D. B.,
O'Brien, D. J.,
Gorman, J. A.,
and Carman, G. M.
(1998)
J. Biol. Chem.
273,
18992-19001 |
43. |
Hatch, G. M.,
and McClarty, G.
(1996)
J. Biol. Chem.
271,
25810-25816 |
44. | Cleland, W. W. (1979) Methods Enzymol. 63, 103-139[Medline] [Order article via Infotrieve] |